Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.

@article{Vaishampayan2010SafetyEP,
  title={Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.},
  author={Ulka Vaishampayan and Angelika M. Burger and Edward A. Sausville and Lance K. Heilbrun and Jing Li and Margit N Horiba and Merrill J. Egorin and Percy S. Ivy and Simon Pacey and Patricia M. LoRusso},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 14},
  pages={3795-804}
}
PURPOSE Heat shock protein (Hsp) 90 inhibition affects the Raf kinase signaling pathway and could enhance antitumor effects of sorafenib, a Raf kinase inhibitor. The combination of sorafenib and tanespimycin [17-allyl-amino-geldanamycin (17-AAG); NSC 330507/KOS-953] was evaluated in a phase I trial with the primary objective of defining a phase II dose. PATIENTS AND METHODS The dose cohorts consisted of fixed continuous oral dosing of 400 mg sorafenib twice daily, starting at 14 days before… CONTINUE READING
23 Citations
37 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

17-(Allylamino)-17Clin Cancer Res

  • AM Burger, HH Fiebig, SF Stinson
  • July 15,
  • 2010
3 Excerpts

Researc on April clincancerres . aacrjournals . org Downloaded from demethoxygeldanamycin activity in human melanoma models

  • AM Burger, HH Fiebig, SF Stinson
  • AntiCancer Drugs
  • 2010

A phase I dose escalation studyof irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patient with solid tumors

  • TseAN, KlimstraDS, GonenM
  • Clin Cancer Res
  • 2008

Similar Papers

Loading similar papers…